ストックスクリーナーアプリを入手
0.5886
0.59%
-0.0035
プレマーケット:
.60
0.0114
+1.94%
前日終値:
$0.5921
開ける：
$0.58
24時間の取引高:
87,672
Relative Volume:
0.25
時価総額：
$2.68M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-4.60%
1か月 パフォーマンス:
-52.53%
6か月 パフォーマンス:
-91.24%
1年 パフォーマンス:
-99.28%
1日の値動き範囲:
$0.56
$0.6099
1週間の範囲:
$0.56
$0.696
52週間の値動き範囲:
$0.56
$108.00
Psyence Biomedical Ltd Stock (PBM) Company Profile
PBM を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PBM
Psyence Biomedical Ltd
|
0.5886 | 2.68M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Psyence Biomedical Ltd (PBM) 最新ニュース
Psyence Biomedical reports corporate update By Investing.com - Investing.com South Africa
Psyence Biomedical reports corporate update - Investing.com
Psyence BioMed Advances in Psychedelic Medicine with Strategic Growth and Clinical Trials - TipRanks
Corporate Update: Psyence Biomedical Ltd Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable Manufacturing - TradingView
Psyence's Game-Changing Phase IIb Trial Takes On Cancer Mental Health Crisis - Stock Titan
Psyence Biomedical Announces Special Shareholder Meeting for Share Consolidation - TipRanks
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Further Strengthens Scientific Advisory Board With Appointment of Dr. Dan J. Stein - The Manila Times
Psyence Biomedical Ltd. (NASDAQ:PBMWW) Short Interest Down 13.1% in February - Defense World
Psyence Biomed expands advisory board with psychopharmacology expert By Investing.com - Investing.com Australia
Psyence Biomed expands advisory board with psychopharmacology expert - Investing.com India
Psyence Biomed Further Strengthens Scientific Advisory Board with Appointment of Dr. Dan J. Stein - TradingView
Top Columbia Psychiatrist Joins Psyence's Psilocybin Clinical Trial Team - StockTitan
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board - The Manila Times
Psyence Biomedical files to sell 13.81M common shares for holders - MSN
Psyence Biomedical Ltd Files For Mixed Shelf Of Up To $75LN -March 04, 2025 at 04:48 pm EST - Marketscreener.com
Psyence Biomedical Ltd Files For Mixed Shelf Of Up To $75LN - TradingView
Psyence Biomed Names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board - GlobeNewswire
Can This Johns Hopkins Psychedelics Expert Accelerate Psyence's Psilocybin Breakthroughs? - StockTitan
Psyence Biomedical Ltd (PBM) Stock: A Value Analysis - The News Heater
Ratio Analysis: Unpacking Psyence Biomedical Ltd (PBM)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Psyence Biomedical Adjusts Financials for Reverse Stock Split - TipRanks
Short Interest in Psyence Biomedical Ltd. (NASDAQ:PBMWW) Decreases By 41.0% - Defense World
Psyence enters into $25M common stock purchase agreement with White Lion Capital - MSN
Psyence Biomedical Issues Pre-Funded Share Purchase Warrant - TipRanks
Psyence Biomed Announces Closing of $2.0 Million Private Placement - The Manila Times
Psyence Biomed (PBM) Raises $2M in Private Placement with Warrant Coverage, Led by H.C. Wainwright - StockTitan
Psyence Biomedical Regains Nasdaq Compliance, Fortifying Market Position - Yahoo Finance
Psyence Biomed announces $2 million private placement By Investing.com - Investing.com Nigeria
PBMPsyence Biomedical Ltd. Common Shares Latest Stock News & Market Updates - StockTitan
Psyence Unveils Private Placement - Baystreet.ca
Psyence Biomed announces $2 million private placement - Investing.com
Psyence Biomed Announces $2.0 Million Private Placement - The Manila Times
Psyence Biomed Secures $2M Private Placement with Strategic Warrant Offering - StockTitan
Psyence Biomedical Achieves Full Nasdaq Compliance, Advances Clinical Trial Plans with $5.6M War Chest - StockTitan
US Stocks To Open Lower As Traders Brace For 'Triple Witching' Hour: Analyst Says End Of The Year Recovery 'Would Not Surprise Anyone' - Benzinga
US Stocks To Open Lower As Traders Brace For 'Triple Witching' Hour: Analyst Says End Of The Year Recovery 'Would Not Surprise Anyone' - Benzinga
Psyence Biomedical Signs Exclusive Licensing Agreement with Optimi Health - TipRanks
Psyence Biomedical Advances in Phase IIb Psilocybin Clinical Trial - TipRanks
Psyence Biomed Highlights Recent Progress on Active Phase IIb Clinical Trial - The Manila Times
Optimi Health to Supply GMP-Certified Psilocybin for Psyence Biomed's Phase IIb Palliative Care Trial - Newsfile
Psyence Biomedical executes binding agreements with Optimi Health - Yahoo Finance
Psyence Biomedical stock soars on binding agreements with Optimi Health - MSN
Psyence Biomed Executes Binding Agreements with Optimi Health Corp - Marketscreener.com
Psyence Biomed Executes Binding Agreements with Optimi Health Corp. - The Manila Times
Psyence Biomedical Ltd (PBM) 財務データ
Psyence Biomedical Ltd (PBM) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
2.00%
大文字化:
|
ボリューム (24 時間):